These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 23807548

  • 21. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T.
    Eur J Pharmacol; 2012 May 15; 683(1-3):166-73. PubMed ID: 22449381
    [Abstract] [Full Text] [Related]

  • 22. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS, Choi HS, Zhao TT, Suh KH, Kwon IH, Choi SO, Lee MK.
    Arch Pharm Res; 2013 Jun 15; 36(6):759-67. PubMed ID: 23539311
    [Abstract] [Full Text] [Related]

  • 23. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.
    Neurobiol Dis; 2013 Dec 15; 60():108-14. PubMed ID: 24004632
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.
    Neurobiol Dis; 2006 Jun 15; 22(3):586-98. PubMed ID: 16531050
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP, Blunt SB, Dexter DT.
    Mov Disord; 2001 May 15; 16(3):424-34. PubMed ID: 11391735
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM, Parr-Brownlie LC, Duncan EJ, Black MA, Gemmell NJ, Dearden PK, Reynolds JN.
    Neuroscience; 2016 Jun 02; 324():238-51. PubMed ID: 26968766
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Solís O, García-Montes JR, Garcia-Sanz P, Herranz AS, Asensio MJ, Kang G, Hiroi N, Moratalla R.
    Neurobiol Dis; 2017 Jun 02; 102():133-139. PubMed ID: 28315782
    [Abstract] [Full Text] [Related]

  • 33. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Nascimento GC, Bariotto-Dos-Santos K, Leite-Panissi CRA, Del-Bel EA, Bortolanza M.
    Neurotox Res; 2018 Nov 02; 34(4):799-807. PubMed ID: 29611150
    [Abstract] [Full Text] [Related]

  • 34. The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats.
    Lorenc-Koci E, Kamińska K, Lenda T, Konieczny J.
    Molecules; 2024 Sep 11; 29(18):. PubMed ID: 39339313
    [Abstract] [Full Text] [Related]

  • 35. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K, Ferger B.
    Neurobiol Dis; 2008 Feb 11; 29(2):210-20. PubMed ID: 17920284
    [Abstract] [Full Text] [Related]

  • 36. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Tronci E, Napolitano F, Muñoz A, Fidalgo C, Rossi F, Björklund A, Usiello A, Carta M.
    Exp Neurol; 2017 Nov 11; 297():73-81. PubMed ID: 28757258
    [Abstract] [Full Text] [Related]

  • 37. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
    Gomes MZ, Raisman-Vozari R, Del Bel EA.
    Brain Res; 2008 Apr 08; 1203():160-9. PubMed ID: 18313645
    [Abstract] [Full Text] [Related]

  • 38. Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
    Bortolanza M, Padovan-Neto FE, Cavalcanti-Kiwiatkoski R, Dos Santos-Pereira M, Mitkovski M, Raisman-Vozari R, Del-Bel E.
    Philos Trans R Soc Lond B Biol Sci; 2015 Jul 05; 370(1672):. PubMed ID: 26009769
    [Abstract] [Full Text] [Related]

  • 39. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 05; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 40. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 05; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.